Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Amlodipine ameliorates myocardial hypertrophy by inhibiting EGFR phosphorylation.

Authors: Liao, Y  Asakura, M  Takashima, S  Kato, H  Asano, Y  Shintani, Y  Minamino, T  Tomoike, H  Hori, M  Kitakaze, M 
Citation: Liao Y, etal., Biochem Biophys Res Commun. 2005 Feb 25;327(4):1083-7.
Pubmed: (View Article at PubMed) PMID:15652507
DOI: Full-text: DOI:10.1016/j.bbrc.2004.12.112

The effects of long-acting calcium channel blockers on pressure overload-induced cardiac hypertrophy have been little studied in experimental animals and the underlying mechanisms are not fully understood. We previously reported that cardiomyocyte hypertrophy could be induced via phosphorylation of the epidermal growth factor receptor (EGFR). In this study, we investigated whether amlodipine attenuates cardiac hypertrophy by inhibiting EGFR phosphorylation. We found that amlodipine dose-dependently inhibited epinephrine-induced protein synthesis and EGFR phosphorylation in cultured neonatal rat cardiomyocytes. Our in vivo study revealed that amlodipine could ameliorate myocardial hypertrophy induced by transverse aortic constriction (TAC) in C57/B6 mice. One week after TAC, amlodipine treatment (3 mg/kg/day) significantly reduced the heart-to-body weight ratio (6.04 +/- 0.16 mg/g vs. 6.90 +/- 0.45 mg/g in untreated TAC mice, P < 0.01). These results indicate that amlodipine ameliorates cardiomyocyte hypertrophy via inhibition of EGFR phosphorylation.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 1580954
Created: 2006-09-06
Species: All species
Last Modified: 2006-09-06
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.